MedTrace Logo

The Role of Meat-borne Carcinogens in Pancreatic Cancer

NCT01092689 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2020-06-26

No results posted yet for this study

Summary

We propose to recruit subjects scheduled for pancreatectomy as a treatment for pancreatic cancer. These subjects will ingest a very low dose of radiolabeled PhIP, a meat-derived carcinogen, and a small amount of resected tissue (waste) will be analyzed with highly sensitive technology to determine if this carcinogen binds to DNA in the pancreas.

Conditions

  • Pancreas Cancer

Interventions

DRUG

PhiP

1 capsule of 84 micrograms; 15.6 micro-curies \[14C\]PhIP

Sponsors & Collaborators

  • University of Arkansas

    collaborator OTHER

  • Lawrence Livermore National Laboratory

    collaborator OTHER

  • University of Minnesota

    lead OTHER

Principal Investigators

  • Kristin E Anderson, PhD · University of Minnesota

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01092689 on ClinicalTrials.gov